Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 30, 2015, Pages E4007-E4016

  Mockenhaupt, Stefan ^a,c   Grosse, Stefanie ^a   Rupp, Daniel ^a,b   Bartenschlager, Ralf ^a,b   Grimm, Dirk ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

AAV; Adeno associated viral vector; Off targeting; RNA interference; Short hairpin RNA

Indexed keywords

MICRORNA; RNA; SHORT HAIRPIN RNA; 3' UNTRANSLATED REGION; DNA; GREEN FLUORESCENT PROTEIN; MIRN122 MICRORNA, HUMAN; OLIGONUCLEOTIDE; SMALL INTERFERING RNA;

ADENO ASSOCIATED VIRUS; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA INTERFERENCE; 3' UNTRANSLATED REGION; BINDING SITE; CHEMISTRY; DEPENDOPARVOVIRUS; GENETICS; GENOTYPE; HEK293 CELL LINE; HEPACIVIRUS; METABOLISM; PHYSIOLOGY; PLASMID; TUMOR CELL LINE; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; HEPATITIS C VIRUS;

3' UNTRANSLATED REGIONS; BINDING SITES; CELL LINE, TUMOR; DEPENDOVIRUS; DNA; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GENOTYPE; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HEPACIVIRUS; HUMANS; MICRORNAS; OLIGONUCLEOTIDES; PLASMIDS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS REPLICATION;

EID: 84938150485     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510476112     Document Type: Article

References (72)

1. Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6):1262-1278.
2. Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457(7228):426-433.
3. Giering JC, Grimm D, Storm TA, Kay MA (2008) Expression of shRNA from a tissuespecific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 16(9):1630-1636.
4. Grimm D, et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441(7092):537-541.
5. Jackson AL, Linsley PS (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9(1):57-67.
6. Jackson AL, et al. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21(6):635-637.
7. Jackson AL, et al. (2006) Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12(7):1179-1187.
8. Vickers TA, et al. (2009) Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 'Slicer' independent and can be mediated by Ago1. Nucleic Acids Res 37(20):6927-6941.
9. Adamson B, Smogorzewska A, Sigoillot FD, King RW, Elledge SJ (2012) A genomewide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat Cell Biol 14(3):318-328.
10. Schultz N, et al. (2011) Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-p pathway and reveal microRNA regulation of TGFBR2. Silence 2:3.
11. Schürmann N, Trabuco LG, Bender C, Russell RB, Grimm D (2013) Molecular dissection of human Argonaute proteins by DNA shuffling. Nat Struct Mol Biol 20(7):818-826.
12. Gu S, et al. (2011) Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proc Natl Acad Sci USA 108(22):9208-9213.
13. Kwak PB, Tomari Y (2012) The N domain of Argonaute drives duplex unwinding during RISC assembly. Nat Struct Mol Biol 19(2):145-151.
14. Winter J, Diederichs S (2011) Argonaute proteins regulate microRNA stability: Increased microRNA abundance by Argonaute proteins is due to microRNA stabilization. RNA Biol 8(6):1149-1157.
15. Winter J, Diederichs S (2013) Argonaute-3 activates the let-7a passenger strand microRNA. RNA Biol 10(10):1631-1643.
16. ∗ species has substantial influence on microRNA and 3' UTR evolution. Nat Struct Mol Biol 15(4):354-363.
17. Khvorova A, Reynolds A, Jayasena SD (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell 115(2):209-216.
18. Schwarz DS, et al. (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115(2):199-208.
19. Tomari Y, Zamore PD (2005) Perspective: Machines for RNAi. Genes Dev 19(5):517-529.
20. Fellmann C, et al. (2011) Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell 41(6):733-746.
21. Betancur JG, Tomari Y (2012) Dicer is dispensable for asymmetric RISC loading in mammals. RNA 18(1):24-30.
22. Noland CL, Doudna JA (2013) Multiple sensors ensure guide strand selection in human RNAi pathways. RNA 19(5):639-648.
23. Noland CL, Ma E, Doudna JA (2011) siRNA repositioning for guide strand selection by human Dicer complexes. Mol Cell 43(1):110-121.
24. Grimm D (2009) Asymmetry in siRNA design. Gene Ther 16(7):827-829.
25. Gu S, et al. (2012) The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in vivo. Cell 151(4):900-911.
26. Boudreau RL, Spengler RM, Davidson BL (2011) Rational design of therapeutic siRNAs: Minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther 19(12):2169-2177.
27. Ding H, Liao G, Wang H, Zhou Y (2007) Asymmetrically designed siRNAs and shRNAs enhance the strand specificity and efficacy in RNAi. J RNAi Gene Silencing 4(1):269-280.
28. McIntyre GJ, Yu YH, Lomas M, Fanning GC (2011) The effects of stem length and core placement on shRNA activity. BMC Mol Biol 12:34.
29. Börner K, et al. (2013) Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic Acids Res 41(21):e199.
30. Liu YP, Schopman NC, Berkhout B (2013) Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res 41(6):3723-3733.
31. Yang JS, et al. (2010) Conserved vertebrate mir-451 provides a platform for Dicerindependent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci USA 107(34):15163-15168.
32. Yang JS, Maurin T, Lai EC (2012) Functional parameters of Dicer-independent microRNA biogenesis. RNA 18(5):945-957.
33. Cifuentes D, et al. (2010) A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science 328(5986):1694-1698.
34. Diederichs S, Haber DA (2007) Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell 131(6):1097-1108.
35. Haraguchi T, et al. (2012) A potent 2'-O-methylated RNA-based microRNA inhibitor with unique secondary structures. Nucleic Acids Res 40(8):e58.
36. Haraguchi T, Ozaki Y, Iba H (2009) Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res 37(6):e43.
37. Grimm D, Kay MA (2003) From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 3(4):281-304.
38. Krönke J, et al. (2004) Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol 78(7):3436-3446.
39. Lee CH, Kim JH, Lee SW (2013) Prospects for nucleic acid-based therapeutics against hepatitis C virus. World J Gastroenterol 19(47):8949-8962.
40. Ma H, et al. (2014) Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers. Gastroenterology 146(1):63-66.
41. Pei Z, et al. (2013) Adenovirus vectors lacking virus-associated RNA expression enhance shRNA activity to suppress hepatitis C virus replication. Sci Rep 3:3575.
42. Yokota T, et al. (2003) Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 4(6):602-608.
43. Grimm D, et al. (2008) In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 82(12):5887-5911.
44. Xie J, et al. (2012) Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods 9(4):403-409.
45. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309(5740):1577-1581.
46. Lanford RE, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962):198-201.
47. Janssen HL, et al. (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368(18):1685-1694.
48. Ottosen S, et al. (2015) In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother 59(1):599-608.
49. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB (2015) miR-122-a key factor and therapeutic target in liver disease. J Hepatol 62(2):448-457.
50. Bühler S, Bartenschlager R (2012) New targets for antiviral therapy of chronic hepatitis C. Liver Int 32(Suppl 1):9-16.
51. Welch NM, Jensen DM (2015) Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int 35(Suppl 1):11-17.
52. Fire A, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806-811.
53. Boudreau RL, Martins I, Davidson BL (2009) Artificial microRNAs as siRNA shuttles: Improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17(1):169-175.
54. Boudreau RL, Monteys AM, Davidson BL (2008) Minimizing variables among hairpinbased RNAi vectors reveals the potency of shRNAs. RNA 14(9):1834-1844.
55. Bak RO, Hollensen AK, Primo MN, Sørensen CD, Mikkelsen JG (2013) Potent microRNA suppression by RNA Pol II-transcribed 'Tough Decoy' inhibitors. RNA 19 (2) 280-293.
56. Kienle E, et al. (2012) Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling. J Vis Exp Apr. 2(62):3819.
57. Dallas A, et al. (2012) Right- and left-loop short shRNAs have distinct and unusual mechanisms of gene silencing. Nucleic Acids Res 40(18):9255-9271.
58. Hollensen AK, Bak RO, Haslund D, Mikkelsen JG (2013) Suppression of microRNAs by dual-targeting and clustered Tough Decoy inhibitors. RNA Biol 10(3):406-414.
59. Wilson JA, Richardson CD (2005) Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 79(11):7050-7058.
60. Lisowski L, Elazar M, Chu K, Glenn JS, Kay MA (2013) The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA. Nucleic Acids Res 41(6):3688-3698.
61. Smith RM, Smolic R, Volarevic M, Wu GY (2007) Positional effects and strand preference of RNA interference against hepatitis C virus target sequences. J Viral Hepat 14(3):194-212.
62. Bassik MC, et al. (2009) Rapid creation and quantitative monitoring of high coverage shRNA libraries. Nat Methods 6(6):443-445.
63. Bassik MC, et al. (2013) A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell 152(4):909-922.
64. Kampmann M, Bassik MC, Weissman JS (2013) Integrated platform for genome-wide screening and construction of high-density genetic interaction maps in mammalian cells. Proc Natl Acad Sci USA 110(25):E2317-E2326.
65. Grimm D, et al. (2010) Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest 120(9):3106-3119.
66. Beer S, et al. (2010) Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther 18(1):161-170.
67. Chen CC, et al. (2007) Long-term inhibition of hepatitis B virus in transgenic mice by doublestranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther 14(1):11-19.
68. Matsushita T, et al. (1998) Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5(7):938-945.
69. Gao GP, et al. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99(18):11854-11859.
70. Grimm D (2002) Production methods for gene transfer vectors based on adenoassociated virus serotypes. Methods 28(2):146-157.
71. Lohmann V (2009) HCV replicons: Overview and basic protocols. Methods Mol Biol 510:145-163.
72. Meister G, et al. (2004) Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 15(2):185-197.